4'-amino-3'-chloro-N-(tert-butyl)[1,1'-biphenyl]-2-sulfonamide | 288309-49-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-amino-3'-chloro-N-(tert-butyl)[1,1'-biphenyl]-2-sulfonamide
• 英文别名: 2'-N-tert-butylaminosulfonyl-3-chloro-[1,1']-biphenyl-4-ylamine；2-(4-amino-3-chlorophenyl)-N-tert-butylbenzenesulfonamide
• CAS: 288309-49-9
• 化学式: C₁₆H₁₉ClN₂O₂S
• 分子量: 338.858
• InChiKey: RHIIPHIJGLGBRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4'-amino-3'-chloro-N-(tert-butyl)[1,1'-biphenyl]-2-sulfonamide 在 三甲基铝 、 tin(ll) chloride 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Nonbenzamidine tetrazole derivatives as factor Xa inhibitors

  摘要：

  Factor Xa (fXa) is an important serine protease that holds the central position linking the intrinsic and extrinsic activation mechanisms in the blood coagulation cascade. Therefore, inhibition of fXa has potential therapeutic applications in the treatments of both arterial and venous thrombosis. Herein we describe a series of tetrazole fXa inhibitors containing benzamidine mimics as the P, substrate, of which the aminobenzisoxazole moiety was found to be the most potent benzamidine mimic. SR374 (12) inhibits fXa with a K-i value of 0.35 nM and is very selective for fXa over thrombin and trypsin. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00951-4
• 作为产物：
  描述：

  2-氯-4-碘苯胺 、 2-(叔丁基氨基)磺酰基苯硼酸 在 四(三苯基膦)钯 sodium hydroxide 作用下， 以 水 、 异丙醇 、 甲苯 为溶剂， 反应 4.0h， 以53%的产率得到4'-amino-3'-chloro-N-(tert-butyl)[1,1'-biphenyl]-2-sulfonamide
  参考文献：
  名称：

  Inhibitors of factor Xa

  摘要：

  揭示了针对哺乳动物因子Xa具有活性的新化合物、它们的盐和相关组合物。这些化合物在体外或体内用于预防或治疗凝血障碍。

  公开号：

  US06673817B1

文献信息

• Design, Synthesis, and Biological Evaluation of Potent and Selective Amidino Bicyclic Factor Xa Inhibitors
  作者：Qi Han、Celia Dominguez、Pieter F. W. Stouten、Jeongsook M. Park、Daniel E. Duffy、Robert A. Galemmo、Karen A. Rossi、Richard S. Alexander、Angela M. Smallwood、Pancras C. Wong、Matthew M. Wright、Joseph M. Luettgen、Robert M. Knabb、Ruth R. Wexler

  DOI：10.1021/jm000113t

  日期：2000.11.1

  cascade. A novel series of fXa inhibitors incorporating an amidino 6,5-fused bicyclic moiety at the P1 position has been designed and synthesized based on molecular modeling studies. Structure-activity relationship (SAR) studies have led to selective subnanomolar fXa inhibitors. The most potent fXa inhibitor in this series (72, SE170) has a potent inhibition constant (K(i) = 0.3 nM), is 350-fold selective

  血栓性疾病是死亡和发病的主要原因。Xa因子（fXa）在凝血级联反应中的正常稳态和异常血管内血栓形成的调节中起着至关重要的作用。基于分子模型研究，已经设计并合成了一系列新的fXa抑制剂，这些抑制剂在P1位置掺入了酰胺基6，5-稠合的双环部分。结构活性关系（SAR）研究已导致选择性的纳摩尔fXa抑制剂。该系列中最有效的fXa抑制剂（72，SE170）具有有效的抑制常数（K（i）= 0.3 nM），对fXa的选择性是胰蛋白酶的350倍，并且在兔动脉硬化中也显示出良好的体内功效静脉血栓形成模型（ID（50）= 0.14 micromol / kg / h）。完成了与牛胰蛋白酶复合的X射线晶体结构72
• Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 2
  作者：Mimi L. Quan、Christopher D. Ellis、Ann Y. Liauw、Richard S. Alexander、Robert M. Knabb、Gilbert Lam、Matthew R. Wright、Pancras C. Wong、Ruth R. Wexler

  DOI：10.1021/jm980406a

  日期：1999.7.1

  Intravascular clot formation is an important factor in a number of cardiovascular diseases, Therefore, the prevention of blood coagulation has become a major target for new therapeutic agents. One attractive approach is the inhibition of factor Xa (FXa), the enzyme directly responsible for thrombin activation. Herein we report a series of isoxazoline derivatives which are potent FXa inhibitors. Optimization of the side chain at the quaternary position of the isoxazoline ring led to SK549 which showed subnanomolar FXa potency (K-i 0.52 nM). SK549 shows good selectivity for FXa compared to thrombin and trypsin, potent antithrombotic effect in the rabbit arterio-venous thrombosis model, and improved pharmacokinetics relative to other compounds evaluated from this series.
• Design, synthesis, and SAR of substituted acrylamides as factor Xa inhibitors
  作者：Yonghong Song、Lane Clizbe、Chhaya Bhakta、Willy Teng、Wenhao Li、Yanhong Wu、Zhaozhong Jon Jia、Penglie Zhang、Lingyan Wang、Brandon Doughan、Ting Su、James Kanter、John Woolfrey、Paul Wong、Brian Huang、Katherine Tran、Uma Sinha、Gary Park、Andrea Reed、John Malinowski、Stan Hollenbach、Robert M. Scarborough、Bing-Yan Zhu

  DOI：10.1016/s0960-894x(02)00199-3

  日期：2002.6

  Substituted acrylamides were used as templates that bridge P1 and P4 binding elements, resulting in a series of potent sub-nanomolar) and selective factor Xa inhibitors. In this template, cis-geometry of P1 and P4 ligands is highly preferred. SAR on the substituting groups, as well as on modification of P1 and P4 moieties is described. Compounds in this series show good in vivo efficacy in animal models. (C) 2002 Elsevier Science Ltd. All rights reserved.
• Design and synthesis of factor Xa inhibitors and their prodrugs
  作者：Yonghong Song、Lane Clizbe、Chhaya Bhakta、Willy Teng、Paul Wong、Brian Huang、Katherine Tran、Uma Sinha、Gary Park、Andrea Reed、Robert M Scarborough、Bing-Yan Zhu

  DOI：10.1016/s0960-894x(02)00921-6

  日期：2003.1

  In addition to our previously reported fluoro acrylamides Xa inhibitors 2 and 3, a series of potent and novel cyclic diimide amidine compounds has been identified. In efforts to improve their oral bioavailability, replacement of the amidine group with methyl amidrazone: gives compounds of moderate potency (14, IC50 = 0.028 muM). In the amidoxime prodrug approach, the amidoxime compounds show good oral bioavailability in rats and dogs. High plasma level of prodrug 26 and significant concentration of active drug 26a were obtained upon oral administration of prodrug 26 in rats. (C) 2002 Elsevier Science Ltd. All rights reserved.
• Substituted acrylamides as factor Xa inhibitors: improving bioavailability by P1 modification
  作者：Yonghong Song、Lane Clizbe、Chhaya Bhakta、Willy Teng、Wenhao Li、Paul Wong、Brian Huang、Uma Sinha、Gary Park、Andrea Reed、Robert M Scarborough、Bing-Yan Zhu

  DOI：10.1016/s0960-894x(02)00304-9

  日期：2002.8

  To overcome the low bioavailability of our substituted acrylamide P1 benzamidine factor Xa inhibitors reported previously, neutral and less basic groups were used to replace the benzamidine. As a result, a series of P1 aminoisoquinoline substituted acrylamide Xa inhibitors was identified to be potent, selective, and orally bioavailable. Modification of P4 moiety of these compounds further improved their pharmacokinetic properties. (C) 2002 Elsevier Science Ltd. All rights reserved.